key: cord-1001042-3ii8pj4i
authors: Mishra, Ajay Kumar; Sahu, Kamal Kant; Lal, Amos
title: Reporting of all cardiac medications and their outcome in COVID ‐ 19
date: 2020-04-08
journal: J Med Virol
DOI: 10.1002/jmv.25843
sha: 500060f9f5cb825ec89513d3b7013fb85f4e43b0
doc_id: 1001042
cord_uid: 3ii8pj4i

We read with much interest the article “Organ‐ protective effect of Angiotensin Converting Enzyme 2 and its Effect on the prognosis of COVID ‐19” by Cheng et al in your esteemed Journal. Authors have discussed the theoretical basis of Angiotensin Converting Enzyme 2 in improving outcome of COVID – 19 patients(1). This article is protected by copyright. All rights reserved.

understanding the multiple factors which contribute to the pathogenesis and outcome.

We have the following comments.

In a study by Cao et We agree with the authors regarding the fact that COVID related organ damage and mortality is higher among patients with prior cardiovascular disease including hypertension, coronary artery disease, and heart failure. It is known that these patients have increased ACE-2 as compared to normal individuals 5 . Whether reninangiotensin-aldosterone system inhibitors worsen clinical outcome in patient with COVID -19 secondary to increasing ACE-2 levels continues to be a continuous debate awaiting prospective clinical data. Either these cardiac agents are inappropriately being stopped in patient who require them (i.e. Heart failure) or are inappropriately being continued in patients at risk of harm (hypotensive, acute renal injury). While down regulation of ACE -2 has been shown to worsen lung injury, among patients with upregulated ACE-2 secondary to RAAS inhibition outcome has not yet been This article is protected by copyright. All rights reserved.

Organ-protective Effect of Angiotensinconverting Enzyme 2 and its Effect on the Prognosis of COVID-19

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Are certain drugs associated with enhanced mortality in COVID-19?

Update on 3rd

Coronavirus Outbreak of 21st Century

COVID-19 and the cardiovascular system

Accepted Article

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 0(0)

Losartan for Patients With COVID-19 Not Requiring Hospitalization -Full Text View -ClinicalTrials

This article is protected by copyright. All rights reserved